Lopinavir/Ritonavir Affects Pharmacokinetic Exposure of Artemether/Lumefantrine in HIV-Uninfected Healthy Volunteers
- 1 August 2009
- journal article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 51 (4), 424-429
- https://doi.org/10.1097/qai.0b013e3181acb4ff
Abstract
OBJECTIVES: Antimalarial combination therapy is used in persons with HIV infection in the absence of data on drug interactions. The objective of this study was to investigate the pharmacokinetics (PK) of antimalarial combination artemether/lumefantrine (AL) when administered with the protease inhibitor combination lopinavir/ritonavir (LPV/r) in HIV-uninfected healthy volunteers to determine if important drug interactions exist between these agents. DESIGN: Open-label study in healthy HIV-seronegative adults. METHODS: Participants received standard 6-dose treatment courses of AL 80/480 mg twice daily on days 1-4 and 28-31. LPV/r 400/100 mg twice daily was administered on days 16-41 after a 2-week washout period. Plasma concentrations of AL, dihydroartemisinin (DHA, artemether metabolite), lopinavir, and ritonavir were measured. RESULTS: PK of lumefantrine was influenced by LPV/r resulting in 2- to 3-fold increases in area under the curve (AUC) (AUC0-264: 413 versus 931 h.microg.mL; AUC0-inf: 456 versus 1073 h.microg.mL). For artemether, trends toward Cmax and AUC decreases (Cmax 14.3 versus 11.2 ng/mL and 42.7-62.0 versus 25.9-40.5 h.ng.mL for AUC) were noted during coadministration. For DHA, decreases in Cmax (58.8 versus 37.3 ng/mL) and AUC (190-198 versus 104-109 h.ng.mL) were observed during coadministration without changes in DHA:artemether AUC ratios. AL did not affect LPV/r PK. CONCLUSIONS: Coadministration of artmether/lumefantrine and LPV/r can be carried out for patients coinfected with malaria and HIV. Formal safety analysis of concomitant therapy should be addressed by future studies among individuals living in malaria-endemic regionsKeywords
This publication has 20 references indexed in Scilit:
- A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasmaJournal of Chromatography B, 2008
- High Risk of Neutropenia in HIV‐Infected Children following Treatment with Artesunate plus Amodiaquine for Uncomplicated Malaria in UgandaClinical Infectious Diseases, 2008
- Combination Therapy for Uncomplicated Falciparum Malaria in Ugandan ChildrenJAMA, 2007
- Hepatotoxicity Due to a Drug Interaction between Amodiaquine plus Artesunate and EfavirenzClinical Infectious Diseases, 2007
- Amodiaquine Metabolism is Impaired by Common Polymorphisms in CYP2C8: Implications for Malaria Treatment in AfricaClinical Pharmacology & Therapeutics, 2007
- High throughput assay for the determination of lumefantrine in plasmaJournal of Chromatography B, 2005
- The potential for interactions between antimalarial and antiretroviral drugsAIDS, 2005
- The global distribution of clinical episodes of Plasmodium falciparum malariaNature, 2005
- BURULI ULCER AND SCHISTOSOMIASIS: NO ASSOCIATION FOUNDThe American Journal of Tropical Medicine and Hygiene, 2004
- Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort studyThe Lancet, 2000